The involvement of galectins as pleiotropic regulators of cell adhesion and growth in disease progression explains the interest to define their ligand-binding properties. Toward this end, it is desirable to approach in vivo conditions to attain medical relevance. In order to simulate physiological conditions with cell surface glycans as recognition sites and galectins as mediators of intercellular contacts we developed an assay using galectin-loaded Raji cells. The extent of surface binding of fluorescent neoglycoconjugates depended on the lectin presence and the type of lectin, the nature of the probes' carbohydrate headgroup and the density of unsubstituted β-galactosides on the cell surface. Using the most frequently studied galectins-1 and -3, application of this assay led to rather equal binding levels for linear and branched oligomers of N-acetyllactosamine. A clear preference of galectin-3 for α1-3-linked galactosylated lactosamine was noted. In parallel, a panel of 24 neoglycoconjugates was tested as inhibitors of galectin binding from solution to N-glycans of surface-immobilized asialofetuin. These two assays differ in presentation of the galectin and ligand, facilitating identification of assay-dependent properties. Under the condition of the cell assay, selectivity among oligosaccharides for the lectins was higher, and extraordinary affinity of galectin-1 to 3 -O-sulfated probes in a solid-phase assay was lost in the cell assay. Having introduced and validated a cell assay, the comprehensive profiling of ligand binding to cell-surface-presented galectins is made possible.
Introduction
The cell surface presents a wide variety of sugar-encoded signals to the environment. They can be translated into responses such as adhesion or growth control by endogenous lectins (Gabius 2006) . In this respect, the spatially accessible determinants at the tip of glycan antennae will likely be preferential contact sites. Homing primarily in on these often-substituted β-galactosides, the members of the galectin family are receiving special attention owing to their emerging involvement in various clinically relevant processes. For instance, galectins factor into immune regulation as well as tumor progression and spread (Leffler 2004; Liu 2005; Liu and Rabinovich 2005) . The presently accrued insights into the functional spectrum of galectins in vivo predict an exquisite fine-tuning in the structure-function relation between individual aspects of the glycomic profile and these lectins, and work on model (neo)glycoproteins has even revealed the impact of topological factors (e.g., substitutions in the glycan core or altering local density) on affinity (Wu et al. 2006; André et al. 2007) . It is thus an obvious aim to define ligand selection by different galectins, at best under in vitro/in vivo conditions.
A series of methods has so far been used to map the binding of glycan ligands to galectins, starting with classical inhibition of hemagglutination (Teichberg et al. 1975 ). As such, solidphase assays with surface-immobilized (neo)glycoconjugates or glycans and labeled galectins or determination of direct ligand binding in solution using fluorescence polarization, frontal affinity chromatography, and isothermal titration calorimetry showed merit to detect differences in binding properties among galectins (Leffler and Barondes 1986; Lee et al. 1990; Ahmad et al. 2002; Hirabayashi et al. 2002; Sörme et al. 2004; Leppänen et al. 2005) . In order to substitute the artificial matrix by a physiological surface, the design of the inhibition assay had been extended to using a human tumor or Chinese hamster ovary cells in vitro Patnaik et al. 2006 ). This experimental setting with cells, the multivalency of galectins apparent from their activity as hemagglutinins and the versatility of neoglycoconjugates, serving as potent lectin ligands (Rapoport et al. 2007 ), prompted us to explore the following approach: to combine availability of a panel of labeled neoglycoconjugates, which present different carbohydrate headgroups, with cell surface binding of galectins. The aim was to develop a new cell-based type of specificity assay for galectins. Intuitively, effector functionality of the lectins implies full cis saturation of their binding sites by endogenous ligands. Of note in this respect, the natural presentation of galectin-1 on SK-N-MC neuroblastoma cells was shown to maintain stoichiometric accessibility of the homodimeric lectin for its ligand ganglioside GM1 (Kopitz et al. 1998) . We therefore proposed that binding of bi-to multivalent lectins to a cell surface can entail to decorate cells with accessible binding sites for a labeled neoglycoconjugate when using the carrier-immobilized glycans at a noninhibitory concentration. The advantages of this assay will be (a) to avoid protein labeling; (b) to map binding properties of galectins when bound to naturally complex glycans, a factor which can affect global aspects of the lectin structure (He et al. 2003); to consider potential for secondary effects on a natural surface (Horan et al. 1999) .
In what follows, we first report on the technical aspects of this new assay procedure. A cell line, which lacks endogenous production of galectins (Lahm et al. 2004) , was selected as a tool to avoid confounding data interpretation. Having established the experimental protocol, we present results on initial application, testing human galectins-1 and -3 with priority. These two proteins stand out from the galectin family as being the most frequently studied. The measurements revealed characteristic features in the profiles of ligand binding and a so far not described marked intergalectin difference for 3 -O-sulfated ligands. These data were set into relation to results from solidphase assays with the galectins in the solution and asialofetuin as a surface-immobilized ligand. This comparison delineated relative differences in binding properties. The reported validation of the assay and the first results give further research on profiling galectin specificity and on drug design a clear direction.
Results

Loading of Raji cells surface with galectins
The two human galectins and non-cross-reactive antibodies were used to test whether loading of cell surfaces with a reactive lectin could be accomplished. The incubation steps were carried out at 4
• C to minimize lateral mobility in the membrane and cis clustering as well as endocytic uptake. The extent of galectin association with the cell surface critically depended on the protocol for removing the galectin-containing solution. Standard washing in three steps led to a drastic reduction of the fluorescence signal in the ensuing immunocytochemical detection. When a single round of cell pelleting by centrifugation was tested, strong signals comprising nearly the complete cell populations in immunofluorimetric monitoring were measured (Figure 1 ). Thus, cell surfaces can be furnished with galectins-1 and -3. To examine whether this system is a suitable platform for specificity assays, we next tested a panel of fluorescent neoglycoconjugates for binding. Should they associate with cell surfaces depending on the galectin presence, it would mean that the comparative profiling of neoglycoconjugate binding will be feasible. Thus, we set out to test this reasoning experimentally.
Flow cytofluorimetric analysis
The first lesson which emerged from Figures 2 and 3 is that fluorescent neoglycoconjugates could definitely interact with loaded cells. Binding depended on the presence of the galectins (please compare black curves with the gray area of control cells) and the nature of the carbohydrate headgroup (the panel of tested glycocompounds and the changes in fluorescence intensity are summarized in Table I ). Strong signals were invariably recorded for linear and branched N-acetyllactosamine (LN) oligomers. Decreases of oligomer length by presenting only the disaccharide (Le c or LN) or branches lacking galactose reduced the extent of binding (Figures 2 and 3 , Table I ). The agalacto derivative of (GlcNAc) 2 3 ,6 LN consequently had no ligand capacity, underscoring the inherent requirement for accessible galactose residues. The Galβ1-3GalNAc terminus was moderate reactive with galectin-1 when presented in the context of the asialoganglioside GM1 tetrasaccharide but not as a disaccharide. Of note, any sulfated disaccharide tested and α2,3-sialylated Nacetyllactosamine did not bind to galectin-1 presented on Raji cell surfaces.
The binding profile to galectin-3-loaded cells showed not only similarities for LacNAc oligomers but also differences. The LNnT tetrasaccharide with reducing-end Glc terminus was rather reactive and, even more important, an α1,3-galactose extension at LacNAc, known as xenoantigen, proved effective as a docking site (Figure 3 and Table I ). Weak binding was seen for LacdiNAc and the 3 -O-sulfated Le c derivative, and all other compounds listed in Table I were inactive. Evidently, the two galectins not only shared properties but also exhibited distinct characteristics, as summarized in Table I . They led us to examine whether spatial blocking with a plant lectin (peanut agglutinin, Cell assay of galectin specificity PNA) reactive with β-galactosides will delineate differences at the levels of loading and reactivity. We also examined enzymatic treatment of galectin-3 (proteolytic truncation) and cells, reducing the presence of unsubstituted β-galactosides.
Blocking of galectin-binding sites
PNA is reactive with the cell surface in a carbohydratedependent manner leading to 91% positive cells (not shown). Its presence reduced the reactivity of Raji cells for galectin-1 (as probed with LNnT) markedly ( Figure 4A ). In contrast, fluorescence intensity of galectin-3-loaded cells probed with Galα3 LN after PNA treatment was not affected ( Figure 4B ). Epitopes for galectin binding to cell surfaces were thus, at least in part, disparate between the two human lectins. This conclusion is further supported by the enzymatic removal of β-galactosides controlled by PNA recognizing β-galactosides ( Figure 5A ). This process markedly reduced galectin-1 and galectin-3 loading ( Figure 5B ). Desialylation did not affect loading in both cases despite a conspicuous reduction in SNA reactivity, signaling efficient removal of α2,6-linked sialic acid ( Figure 5A ). Evidently, eliminating α2, 6-sialylation will not automatically turn the unmasked β-galactosides into galectin ligands ( Figure 5B ).
The tendency of the chimera-type galectin-3 to pentamerize when in contact to multivalent ligands (Ahmad et al. 2004 ) afforded the opportunity to address the issue whether oligomerization has a bearing on this assay setting. Indeed, proteolytic degradation of the N-terminus mainly involved in oligomerization but not sugar binding nearly abolished signal generation to LNnT as a ligand (Figure 6 ). Cell binding of the potent trisaccharide with α1-3 galactose extension was completely abolished (not shown). Accessibility of galectin-3 for ligands thus depended on the capacity of the chimera-type galectin to efficiently oligomerize.
Sensivity of probe binding to enzymatic treatment of galectin-loaded cells
Physiological ligands of galectins in general include unsubstituted and substituted β-galactosides. In order to infer whether dynamic events after cell surface loading depended on free β-galactoside termini we performed extensive β-galactosidase treatment controlled by the application of the plant lectins DSA and PNA probes to verify the reduction of accessible β-galactosides shown for DSA in Figure 7A . Evidently, we herewith decreased the density of β-galactosides and restricted sites for galectin binding to substituted β-galactosides not susceptible to this enzyme treatment. Immunofluorimetric controls revealed no dissociation of galectins from loaded cells, shown for galectin-3 in Figure 7B . As a consequence of enzyme treatment, the extent of fluorescence intensity for the rather weak ligand LN increased ( Figure 7C, D) . Apparently, unsubstituted cell surface Cell assay of galectin specificity Galβ1-4GlcNAcβ1-6Galβ1-4GlcNAc LN6 L N 3 2 n a n a 20 (GlcNAc) 2 3 ,6 L N 2 2 n a n a β-galactosides, that is cis sites, can have an inhibitory effect on probe binding. The density of reactive sites on the cell surface and ligand properties of the headgroup of the fluorescent neoglycoconjugate appeared to factor into the overall results. This result also underscored the potential for dynamic processes on the cell surface not simulated by solid-phase assays. This aspect and the further parameters setting cell-based experiments apart from the solid-phase system prompted us to examine whether the nature of the assay system may influence the reactivity of glycocompounds for galectins. To address this issue we tested the same panel of neoglycoconjugates (Table I) as inhibitors of galectin binding from the solution to a matrix established by asialofetuin.
Analysis by solid-phase assays
The matrix presented a single glycoprotein, and galectin binding from solution was inhibited in a competitive manner by a panel of neoglycoconjugates. The assay was performed at 4
• C and 37
• C, reaching very similar data (data not shown). With respect to neutral sugars, no major differences in reactivity profiles between galectins-1 and -3 were noted ( Table I ). The α1-3Gal extension did not improve inhibitory reactivity with respect to galectin-3. However, 3 -O-sulfation led to a strong preference for galectin-1 (Table I) . When competing with a neutral ligand as a docking site, both 3 -O-sulfated disaccharides were potent inhibitors for galectin-1 but not for galectin-3. The comparison given in Table I revealed that the nature of the assay conditions (i.e., galectin loading of cells versus free galectin and cell surface ligands versus asialofetuin) affected the reactivity profile of neoglycoconjugates.
Discussion
Emerging evidence reveals the strategic orchestration of cell glycosylation and lectin functionality. Elucidation of the ways the tumor suppressor p16
INK4a can mediate anoikis induction via galectin-1 or the internalization of growth factor receptors bearing β1-6-branches in N-glycans appears to be regulated by galectin-3 is capturing further attention for the activities of the members of the galectin family (Lau et al. 2007 ). These clinical implications add interest to comprehensively define the ligand properties of human galectins in a setting as close as possible to the physiological context. It was the central aim of our report to establish a cell-based assay and validate its application for these two most frequently studied family members.
Toward this end we used the favorable properties of neoglycoconjugates to present carbohydrate ligands in a multivalent manner. This characteristic already facilitated detection of cell surface lectin activity (Rapoport et al. 2007) . By selecting a suitable cell line as a platform for galectin presentation we intended to set up conditions which simulate establishment of intercellular contacts by galectins. By monitoring this new receptor property on the cell surface with a panel of fluorescent neoglycoconjugates a comparative analysis between galectins becomes possible. The presented results enabled us to draw the following conclusions: (a) Cells, which lack the presence of endogenous lectins, were selected to simplify the interpretation of results. Loading was accomplished, and the multivalent neoglycoconjugates obviously formed stable contacts with the presented galectins. Binding of the probes depended on the presence of terminal galactose residues. Cells without the loading step were not reactive. The set-up thus simulated a cell system primed for intercellular contacts. (b) The length of the carbohydrate chain and its degree of branching were important parameters for binding. The disaccharide LacNAc was not effective. This result is in full accord with previous reports of lectin reactivity to LacNAc oligomers when tested with surface-immobilized (neo)glycoproteins (Stowell et al. 2004; Leppänen et al. 2005) . In contrast, oligomer presentation to the galectin in the solution has in general no or minor effects on affinity (Di Virgilio et al. 1999; Bachhawat-Sikder et al. 2001; Ahmad et al. 2002 Ahmad et al. , 2004 Hirabayashi et al. 2002) . Because the crystal structures of human galectins-1 and -3 provide no evidence for a series of LacNAc-specific sites (Seetharaman et al. 1998; López-Lucendo et al. 2004 ), kinetic factors are likely to account for the measured binding preference. (c) To challenge the assay's quality we deliberately added the monitored xenoantigen determinant and LacdiNAc to our test panel. Both determinants had been reported to target galectin-3 (van den Berg et al. 2004; Jin et al. 2006) . Our cell assay confirmed avid binding and revealed conspicuous selectivity. Although being structurally closely related and sharing affinity to certain natural ligands such as the pentasaccharide of ganglioside GM1 (Kopitz et al. 1998) , galectins-1 and -3 also have divergent ligand preferences, as revealed by our analysis. The question immediately arises on properties of the other members of this lectin family.
Loading of Raji cell surfaces with galectins
Raji cells (human B-lymphocyte origin, ATCC no. CCL86) were cultured in RPMI-1640 medium supplemented with 10% fetal calf serum and 2 mM glutamine at 37
• C in an atmosphere of 5% CO 2 .
Cells were washed three times with phosphate-buffered saline containing 0.2% BSA (PBA) to deplete the solution of glycoproteins from the serum using centrifugation at 800 rpm/min and 4
• C. Aliquots of the cell suspension (1 × 10 5 cells in 50 µL) were incubated with 50 µL of galectin-containing solution (0.4 mg/mL) for 30 min at 4
• C under gentle agitation on a shaker. Cell pelleting then separated cells from the solution. Loading controls were performed with the galectin-type-specific antibodies and corresponding fluorescent second-step reagents used in incubation steps lasting 20 min at 4
• C. Flow cytometry was performed using a FACScan instrument (Becton-Dickinson, Heidelberg, Germany) equipped with the software WiNMDI 2.8.
Probing the galectin-loaded cells with neoglycoconjugates
Cells loaded with a galectin were centrifuged at 800 rpm/min. The cells (1 × 10 5 per well in 50 µL) were carefully resuspended in PBA and incubated in 50 µL with the Glyc-PAA-fluo probes in PBA (final concentration: 100 µM) for 40 min at 4
• C under gentle agitation. Thereafter, the cells were washed twice with PBA and analyzed by flow cytometry as given above. Mocktreated cells were used as negative control.
Masking of distinct β-galactosides
Raji cells were incubated with the plant lectin PNA in PBA (1 µg/mL) for 30 min at 4
• C. After thorough washing with PBA cells were then loaded with galectins as above followed by probing with fluorescent neoglycoconjugate. After final washing fluorescence profiling was performed by flow cytofluorimetry.
To control glycan accessibility to galectins cells were incubated with neuraminidase (4 U/mL) followed by β-galactosidase, controls for effective hydrolysis were performed by using labeled plant lectins with affinity for α2,3/6-linked sialic acid (MAA-I, SNA) and β-galactosides (PNA). Galectins were loaded on enzyme treated cells, binding of galectins to cells was analyzed with the galectin-type-specific antibodies as described above.
